Skip to main content
. 2023 Oct 5;29(3):e372–e381. doi: 10.1093/oncolo/oyad273

Table 1.

Patient clinicopathologic and metabolic characteristics in the whole cohort.

Characteristics Overall population n = 430 (%)
Age at ICI start
 Median (range) 69.0 (32.0-92.0)
Sex
 Female 142 (33.0%)
 Male 288 (67.0%)
Smoking status
 Current/former 248 (57.0%)
 Never 169 (39%)
 NA 13 (4.0%)
Tumor type
 NSCLC 266 (62.0%)
 RCC 74 (17.0%)
 Melanoma 55 (13.0%)
 Others* 35 (8.0%)
Treatment type
 ICI 373 (87.0%)
 ICI plus chemotherapy 27 (6.0%)
 ICI plus TKI 30 (7.0%)
Treatment line
 First 235 (55.0%)
 ≥ second 195 (45.0%)
ECOG PS
 0-1 385 (89.0%)
 ≥2 45 (10.0%)
Metastatic sites
 0-1 103 (24.0%)
 ≥2 327 (76.0%)
Diagnosis of DM
 No 346 (81.0%)
 Yes 84 (19.0%)
CV disease
 No 293 (68.0%)
 Yes 135 (31.0%)
 NA 2 (1.0%)
Hypertension
 No 189 (44.0%)
 Yes 241 (56.0%)
Statin use
 No 312 (72.0%)
 Yes 115 (27.0%)
 NA 3 (1.0%)
BMI
 Underweight
(BMI < 18.5)
18 (4.2%)
 Normal
(18.5 ≤ BMI ≤ 24.9)
213 (49.5%)
 Overweight
(25 ≤ BMI ≤ 29.9)
135 (31.4%)
 Obese
(BMI ≥ 30)
60 (13.9%)
 NA 4 (0.9%)
TC
 <200 mg/dl 295 (69.0%)
 ≥200 mg/dl 135 (31.0%)
HDL
 < 40 mg/dl (males) or < 50 mg/dl (females) 92 (21.0%)
 ≥ 40 mg/dl (males) or ≥ 50 mg/dl (females) 167 (39.0%)
 NA 171 (40.0%)
LDL
 < 100 mg/dl 150 (35.0%)
 ≥ 100 mg/dl 107 (25.0%)
 NA 173 (40.0%)
TG
 <150 mg/dl 220 (52.0%)
 ≥150 mg/dl 96 (22.0%)
 NA 114 (26.0%)

*Others: urothelial carcinoma, head and neck carcinoma, small cell lung cancer, and breast cancer

Abbreviations: HDL: high-density cholesterol; LDL: low-density cholesterol; ICI: immune checkpoint inhibitor; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; TKI: tyrosine kinase inhibitor; ECOG PS: Eastern Cooperative Oncology Group-Performance Status; DM: diabetes mellitus; BMI: body mass index (kg/m2); NA: not available; TC: total cholesterol; TG: triglycerides.